ABSTRACT

Introduction: Calcineurin inhibitors are currently considered the cornerstone of maintenance immunosuppression in renal transplantation. The extended release formulation of tacrolimus (ER-TAC) was developed to improve drug adherence in these patients. The long-term safety and efficacy of the conversion from the twice-daily tacrolimus to the ER-TAC is still undetermined. Subjects and Methods: Retrospective registry-based single centre study including all renal transplant recipients converted from TAC twice-daily to the ER-TAC on a 1:1 mg basis. We collected biometric data, induction regimens, acute rejection episodes and death. Variables of interest [serum creatinine, blood urea nitrogen, fasting glucose, urinalysis, haemoglobin, TAC dose (mg/kg) and TAC trough levels (ng/ml)] were registered at conversion and 1, 6, 12 months and at last follow-up post-conversion. Results: We analysed 127 patients, 71.9 % male, mean age at conversion (± SD) was 49.8 ± 13.6 years. Conversion occurred at 4.10 ± 3.83 years after transplant and our mean follow-up time was 2.56 ± 0.55 years. TAC trough levels (ng/ml) progressively decreased from pre-conversion to the following stages (pre-conversion: 7.41 ± 2.61 vs. last follow-up: 5.04 ± 1.86, p < 0.001) but no significant dose adjustments were necessary for attaining predetermined target levels. Renal function remained stable and there were no significant differences in glucose metabolism pre and post conversion. No significant adverse effects were verified. There were no episodes of acute rejection throughout the follow-up. Conclusions: The conversion to ER-TAC ensured effective immunosuppression over a follow-up of 2 years suggesting that this formulation is an excellent alternative to the conventional one.

Key-Words: Conversion; extended release; immunosuppression; renal transplantation; tacrolimus.
The need for maintenance immunosuppressive therapy in renal transplantation was soon found indispensable for the prevention of acute rejection and the loss of the renal allograft. The optimal therapy in these patients is still under debate but the role of calcineurin inhibitors (CNI) seems crucial and most transplant centres utilize a regimen with these agents.

Tacrolimus (TAC) is currently considered the first-line CNI for renal transplantation. Several studies have showed superior graft function, better prevention of acute rejection and superior graft survival with comparison to cyclosporine. Non-adherence is one of the most important risk factors for allograft loss over the long-term and the odds of graft failure are reported to be increased sevenfold in these patients. A recent comparison of kidney graft survival rates between Europe and the United States (US) pointed out that non-adherence issues could explain the lower long-term kidney graft survival found in the US. In 2007, an extended release Tacrolimus (ER-TAC) formulation (Advagraf®; Astellas Pharma Inc.) was designed in order to improve adherence by providing a more convenient once-daily dosing. Pharmacokinetic phases I and II studies showed equivalence between the ER-TAC and the twice-daily standard release TAC (BID-TAC). Clinical experience in current practice with the conversion from BID-TAC to an ER formulation has been described in several observational studies with excellent results demonstrated with relation to acute rejection rate and other efficacy and safety considerations. The follow-up of these reports was limited to a maximum of twelve months. Further evaluation is required to access the long-term effects of this conversion.

We aimed to analyse the safety and efficacy of conversion from BID-TAC to an ER formulation in stable kidney transplant recipients, reporting our experience over a longer period.
Conversion from twice-daily tacrolimus to an extended release formulation in stable kidney transplant recipients: 2-year follow-up results of a single centre

6-month post-transplant status, absence of an acute clinical hazardous event (cardiovascular, infectious or rejection episode) and absence of a significant increase (> 0.3 mg/dL) in serum creatinine in the previous 3 months. Patients included attained a pre-conversion TAC-trough level that is within our target values adjusted to transplant time (during the first three months 8-12 ng/ml, during the following year 7-10 ng/ml and thereafter 4-8 ng/ml). Our current induction therapy consists of an anti-IL-2 receptor antibody (Basiliximab) for lower immunological risk patients and a polyclonal anti-lymphocyte antibody for higher risk patients (Re-transplantation, elevated panel-reactive antibody, black-race, younger recipient age and cold ischaemia time > 24 hours). Our standard maintenance immunosuppression regimen consists of triple therapy with the CNI, prednisone and an antimetabolite (mycofenolate mofetil or mycophenolic acid). This therapy is progressively adjusted to the transplant time and the patient's immunological risk according to evidence-based clinical practices.

Conversion started in June 2009 and our reported follow-up leads up to October 2012. We collected biometric variables (body weight, blood pressure), induction and maintenance immunosuppression regimens, acute rejection episodes and death. Laboratory variables of interest (serum creatinine (sCr), blood urea nitrogen, fasting glucose, urinalysis, haemoglobin, TAC dose (mg/kg) and TAC trough levels (ng/ml)) were registered pre-conversion and at 1, 6, 12 months and at last follow-up post-conversion. Glomerular filtration rate (GFR) was estimated from serum creatinine using the Modification of Diet in Renal Disease Study (MDRD-4) equation12. We also reviewed reported side-effects and drug discontinuation motives.

Our primary endpoints were patient and graft survival. Secondary endpoints included episodes of acute rejection and graft function and glucose metabolism evolution.

Statistical analysis was performed using statistical package SPSS 17.0 (SPSS Inc., Chicago, IL, USA) and significance was assessed at the two-tailed 0.05 threshold. For continuous variables means ± standard deviations (SD) are given and for categorical variables frequency and percentages of patients are shown. The paired student’s t-tests or Wilcoxon signed-rank tests, as appropriate, were applied for the study of continuous variables and the Chi-squared test or the Fisher’s exact test were applied in the categorical variables as appropriate.

RESULTS

The analysis included 127 patients (71.9% male). Mean age at conversion was 49.8 ± 13.6 years, mean time from transplantation to conversion was 4.10 ± 3.83 years and our mean follow-up time was 2.56 ± 0.55 years. The patients were transplanted between September 1987 and November 2010 with 10.2% being re-transplantations (second transplant in all), living donor in 7.1% and expanded criteria donor in 43.3%. Twenty-one (16.5%) were considered higher immunological risk patients and received induction therapy with a polyclonal anti-lymphocyte antibody. The aetiology of chronic kidney disease was undetermined in 39.3%, and the main determined causes were chronic glomerulonephritis in 22.0%, autosomal dominant polycystic kidney disease in 12.5 %, chronic interstitial nephritis in 10.2%, hypertension in 7.8% and diabetes in 7.0%.

The mean TAC dose (mg/Kg/day) at conversion was 0.067 ± 0.037 and 12 months post-conversion 0.065 ± 0.032, p = 0.33. At the last follow-up TAC dose significantly decreased to 0.060 ± 0.031, p = 0.004. The TAC trough levels (ng/ml) significantly decreased from pre-conversion to the following stages: pre-conversion: 7.41 ± 2.61, twelve months 6.21 ± 2.50 and at the last follow-up 5.04 ± 1.86, p < 0.001 (Fig. 1). The mean change of these levels at 12 months was -15.7% and at the last follow-up – 31.9%. At conversion, 98.4% of patients were also treated with...
prednisone and 88.1% with an antimetabolite. At the last follow-up, no important changes were observed in concomitant immunosuppression.

Regarding our primary endpoints, we report no deaths throughout the follow-up. Post-conversion graft survival at 12 and 24 months was 100%. One patient returned to dialysis 29 months after conversion due to advanced biopsy-proven interstitial fibrosis and tubular atrophy.

Mean GFR values did not change significantly during follow-up (69.87 ± 23.8 mL/min at conversion versus 71.29 ± 28.7 mL/min at last follow-up, p = 0.105). (Fig. 2)

DISCUSSION

Our centre started the conversion of transplant recipients treated with BID-TAC to the ER-TAC formulation aiming to improve drug adherence. With our practice supported by clinical evidence, we find this to be a key element in the prevention of allograft loss over the long-term. Our results support that the conversion of stable renal transplant recipients treated with BID-TAC to the ER-TAC formulation is safe and efficient up to a medium follow-up of 2 years. To this date, the largest study assessing the safety and efficacy of conversion from BID-TAC to the ER-TAC in maintenance kidney transplant recipients study was restricted to 12-months. This large Spanish multicentre, prospective, observational study (GREAT Study Group) published their results in 2011 and reported that the conversion provided stable renal function, a low acute rejection rate, and good tolerability in stable kidney transplant recipients in the routine clinical practice setting. Several other studies have reported similar results comprehensive to the same maximum follow-up time.

Our analysis is in concordance with published results regarding a progressive TAC trough level decrease after conversion. Some authors opted by increasing their TAC dosage to compensate for this finding. In our study, the mean level change at 12 months of -15.7% was accepted since those values remained within our targets and adjusted to the patient’s transplant time. We significantly reduced the patient’s TAC exposure after the 12 months, according to our centre practices. The unexpected decrease in TAC trough levels has already been questioned regarding a possible subclinical immunological graft damage that could compromise lifelong survival versus a possible benefit in relation with reduced nephrotoxicity. The results of the Symphony study, a large multicentre randomized control study in de novo kidney transplant recipients (n = 1665) showed superior graft function, better prevention of acute rejection and superior graft survival at 12 months with daclizumab induction and low-dose tacrolimus (C0 3–7 ng/ml). Although Prograft® was used in that study, we consider that we can possibly expect the same results with the use of the ER formulation and the addressed targets of TAC trough levels. Although we found no significant need for dose adjustment after conversion to compensate for the TAC trough level decrease, regular monitoring is advised especially if the conversion is performed early after transplantation when
higher targets are in order. This is in agreement with the 2009 KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients6.

Our study has several limitations inherent to its retrospective registry-based single centre design. Conversion to ER-TAC was performed in a selected method, excluding patients with a higher risk for acute rejection during at least 6 months after transplantation, such as a previous acute rejection episode and/or other hazardous events. We, therefore, cannot expand our conclusions to other transplant recipients. Protocol biopsies are actually the only method to detect subclinical rejection and there is evidence of its association with chronic allograft injury and reduced graft survival16,17. Although we cannot exclude this form of injury, our excellent and stable estimated GFR during the follow-up stands against it. We also do not have an independent measure of improved drug adherence with the ER formulation, but there is compelling evidence that reducing dosing frequency can improve adherence and graft outcome18. Randomized control trials are still needed to test interventions to improve adherence in kidney transplant patients.

In conclusion, our study demonstrated the maintenance of effective immunosuppression in patients converted to ER-TAC over a follow-up of more than 2 years, suggesting this to be an excellent alternative to the conventional formulation.

Conflict of interest statement: None declared.

References

Correspondence to:
Dr. Luis Rodrigues
Department of Nephrology, Centro Hospitalar e Universitário de Coimbra. Coimbra, Portugal
Praceta Professor Mota Pinto 3000-075 Coimbra, Portugal.
E-mail: luis.rodrigues@hotmail.com

End page: This work had no support in the form of grants, equipment, drugs, or any combination thereof.